PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

PPFIA1 is upregulated in liver metastasis of breast cancer and is a potential poor prognostic indicator of metastatic relapse.

Abstract Although the oncogenic role of PPFIA1 (liprin-α1) in breast cancer has been reported, whether its dysregulation is associated with metastasis risk or survival outcomes in breast cancer patients is not clear. Our primary data showed that PPFIA1 expression was significantly higher in liver metastatic breast tumors than in the primary tumors. Then, we tried to pool previous annotated genomic data to assess the prognostic value of PPFIA1 in distant metastasis-free survival, the risk of metastatic relapse, and metastatic relapse-free survival in breast cancer patients by data mining in two large databases, Kaplan-Meier plotter and bc-GenExMiner 4.0. Results from Kaplan-Meier plotter showed that although high PPFIA1 expression was generally associated with decreased distant metastasis-free survival in estrogen receptor+ patients, subgroup analysis only confirmed significant association in estrogen receptor+/N- (nodal negative) group (median survival, high PPFIA1 group vs low PPFIA1 cohort: 191.21 vs 236.22 months; hazard ratio: 2.23, 95% confidence interval: 1.42-3.5, p < 0.001), but not in estrogen receptor+/N+ (nodal positive) group (hazard ratio: 1.63, 95% confidence interval: 0.88-3.03, p = 0.12). In estrogen receptor- patients, there was no association between PPFIA1 expression and distant metastasis-free survival, no matter in Nm (nodal status mixed), N-, or N+ subgroups. In bc-GenExMiner 4.0, Nottingham Prognostic Index- and Adjuvant! Online-adjusted analysis validated the independent prognostic value of PPFIA1 in metastatic risks in estrogen receptor+/N- patients. Based on these findings, we infer that high PPFIA1 expression might be an independent prognostic indicator of increased metastatic relapse risk in patients with estrogen receptor+/N- breast cancer, but not in estrogen receptor+/N+ or estrogen receptor- patients.
PMID
Related Publications

Evaluation of vascular endothelial growth factor as a prognostic marker for local relapse in early-stage breast cancer patients treated with breast-conserving therapy.

Patterns of relapse and metastatic spread in HER2-overexpressing breast cancer according to estrogen receptor status.

Discordances in estrogen receptor status, progesterone receptor status, and HER2 status between primary breast cancer and metastasis.

Claudin-2 is an independent negative prognostic factor in breast cancer and specifically predicts early liver recurrences.

β-catenin-independent WNT signaling and Ki67 in contrast to the estrogen receptor status are prognostic and associated with poor prognosis in breast cancer liver metastases.

Authors

Mayor MeshTerms
Keywords

Breast cancer

PPFIA1

metastatic relapse

prognosis

Journal Title tumour biology : the journal of the international society for oncodevelopmental biology and medicine
Publication Year Start




PMID- 28720060
OWN - NLM
STAT- MEDLINE
DA  - 20170719
DCOM- 20170726
LR  - 20170726
IS  - 1423-0380 (Electronic)
IS  - 1010-4283 (Linking)
VI  - 39
IP  - 7
DP  - 2017 Jul
TI  - PPFIA1 is upregulated in liver metastasis of breast cancer and is a potential
      poor prognostic indicator of metastatic relapse.
PG  - 1010428317713492
LID - 10.1177/1010428317713492 [doi]
AB  - Although the oncogenic role of PPFIA1 (liprin-alpha1) in breast cancer has been
      reported, whether its dysregulation is associated with metastasis risk or
      survival outcomes in breast cancer patients is not clear. Our primary data showed
      that PPFIA1 expression was significantly higher in liver metastatic breast tumors
      than in the primary tumors. Then, we tried to pool previous annotated genomic
      data to assess the prognostic value of PPFIA1 in distant metastasis-free
      survival, the risk of metastatic relapse, and metastatic relapse-free survival in
      breast cancer patients by data mining in two large databases, Kaplan-Meier
      plotter and bc-GenExMiner 4.0. Results from Kaplan-Meier plotter showed that
      although high PPFIA1 expression was generally associated with decreased distant
      metastasis-free survival in estrogen receptor+ patients, subgroup analysis only
      confirmed significant association in estrogen receptor+/N- (nodal negative) group
      (median survival, high PPFIA1 group vs low PPFIA1 cohort: 191.21 vs 236.22
      months; hazard ratio: 2.23, 95% confidence interval: 1.42-3.5, p &lt; 0.001), but
      not in estrogen receptor+/N+ (nodal positive) group (hazard ratio: 1.63, 95%
      confidence interval: 0.88-3.03, p = 0.12). In estrogen receptor- patients, there 
      was no association between PPFIA1 expression and distant metastasis-free
      survival, no matter in Nm (nodal status mixed), N-, or N+ subgroups. In
      bc-GenExMiner 4.0, Nottingham Prognostic Index- and Adjuvant! Online-adjusted
      analysis validated the independent prognostic value of PPFIA1 in metastatic risks
      in estrogen receptor+/N- patients. Based on these findings, we infer that high
      PPFIA1 expression might be an independent prognostic indicator of increased
      metastatic relapse risk in patients with estrogen receptor+/N- breast cancer, but
      not in estrogen receptor+/N+ or estrogen receptor- patients.
FAU - Yang, Jing
AU  - Yang J
AD  - 1 Department of Interventional Radiology, The Second Affiliated Hospital of
      Harbin Medical University, Harbin, China.
FAU - Wu, Ning-Ni
AU  - Wu NN
AD  - 2 Department of Medical Oncology, Yijishan Hospital of Wannan Medical College,
      Wuhu, China.
FAU - Huang, De-Jia
AU  - Huang DJ
AD  - 3 Department of Interventional Radiology, Affiliated Tumor Hospital of Guangxi
      Medical University, Nanning, China.
FAU - Luo, Yao-Chang
AU  - Luo YC
AD  - 4 Department of Interventional Radiology, The First Affiliated Hospital of
      Guangxi University of Chinese Medicine, Nanning, China.
FAU - Huang, Jun-Zhen
AU  - Huang JZ
AD  - 4 Department of Interventional Radiology, The First Affiliated Hospital of
      Guangxi University of Chinese Medicine, Nanning, China.
FAU - He, Hai-Yuan
AU  - He HY
AD  - 4 Department of Interventional Radiology, The First Affiliated Hospital of
      Guangxi University of Chinese Medicine, Nanning, China.
FAU - Lu, Hai-Lin
AU  - Lu HL
AD  - 4 Department of Interventional Radiology, The First Affiliated Hospital of
      Guangxi University of Chinese Medicine, Nanning, China.
FAU - Song, Wen-Ling
AU  - Song WL
AD  - 4 Department of Interventional Radiology, The First Affiliated Hospital of
      Guangxi University of Chinese Medicine, Nanning, China.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Tumour Biol
JT  - Tumour biology : the journal of the International Society for Oncodevelopmental
      Biology and Medicine
JID - 8409922
RN  - 0 (Adaptor Proteins, Signal Transducing)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (PPFIA1 protein, human)
RN  - 0 (Receptors, Estrogen)
SB  - IM
MH  - Adaptor Proteins, Signal Transducing/*biosynthesis/genetics
MH  - Adult
MH  - Aged
MH  - Biomarkers, Tumor/*biosynthesis/genetics
MH  - Breast Neoplasms/*genetics/pathology
MH  - Female
MH  - Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Liver Neoplasms/*genetics/pathology/secondary
MH  - Middle Aged
MH  - Neoplasm Metastasis
MH  - Neoplasm Recurrence, Local/genetics/pathology
MH  - Prognosis
MH  - Receptors, Estrogen/*genetics
MH  - Recurrence
OTO - NOTNLM
OT  - Breast cancer
OT  - PPFIA1
OT  - metastatic relapse
OT  - prognosis
EDAT- 2017/07/20 06:00
MHDA- 2017/07/27 06:00
CRDT- 2017/07/20 06:00
AID - 10.1177/1010428317713492 [doi]
PST - ppublish
SO  - Tumour Biol. 2017 Jul;39(7):1010428317713492. doi: 10.1177/1010428317713492.